Liminatus Pharma, Inc. (LIMN)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Liminatus Pharma, Inc. (LIMN) trades at $0.13 with AI Score 25/100 (Grade F). Liminatus Pharma, Inc. is a clinical-stage immuno-oncology company focused on developing novel cancer therapies. Market cap: $3.46M, Sector: Healthcare.
Price live · AI analysis from May 10, 2026Analyst Coverage for LIMN: LIMN does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates LIMN against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
LIMN: 1/1 perspectives are bearish.
How is this calculated? →Liminatus Pharma, Inc. (LIMN) Healthcare & Pipeline Overview
Liminatus Pharma, Inc. is a clinical-stage immuno-oncology company developing novel cancer therapies. Based in La Palma, California, the company operates in the competitive biotechnology sector, focusing on innovative approaches to cancer treatment. With a small team, Liminatus Pharma aims to advance its therapies through clinical trials.
What Is the Investment Thesis for LIMN?
Liminatus Pharma, Inc. presents a high-risk, high-reward investment opportunity typical of early-stage biotechnology companies. The company's focus on immuno-oncology, a rapidly growing field, offers significant potential for value creation if its therapies prove successful in clinical trials. Key value drivers include the advancement of its lead drug candidates through clinical development, potential partnerships with larger pharmaceutical companies, and eventual regulatory approval and commercialization of its therapies. However, the company faces significant risks, including the uncertainty of clinical trial outcomes, the need for substantial additional funding, and intense competition from larger, more established players in the immuno-oncology space. With a market capitalization of $3.46M and a beta of 0.63, Liminatus Pharma exhibits characteristics of a volatile, speculative investment. Successful navigation of these challenges could lead to substantial returns, while failure could result in significant losses.
Based on FMP financials and quantitative analysis
LIMN Key Highlights
- Liminatus Pharma operates as a clinical-stage company, indicating ongoing research and development efforts.
- The company focuses on immuno-oncology, a rapidly evolving field within cancer therapeutics.
- Based in La Palma, California, Liminatus Pharma benefits from access to a vibrant biotechnology ecosystem.
- The company has a small team of three employees, reflecting a lean operational structure.
- With a market capitalization of $3.46M, Liminatus Pharma is a micro-cap company with high growth potential and associated risks.
Who Are LIMN's Competitors?
LIMN is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ANAB AnaptysBio, Inc. | $67.29 | +8.00% | $2.90B | 79 |
| SNDX Syndax Pharmaceuticals, Inc. | $23.12 | +4.69% | $2.05B | 79 |
| ABCL AbCellera Biologics Inc. | $7.69 | -2.29% | $2.35B | 76 |
| CGEN Compugen Ltd. | $2.38 | +1.06% | $225.51M | 76 |
| GLUE Monte Rosa Therapeutics, Inc. | $24.32 | +4.58% | $1.58B | 68 |
| IVBXF Innovent Biologics, Inc. | $10.15 | -13.05% | $17.61B | 68 |
| BCYC Bicycle Therapeutics plc | $4.50 | +3.56% | $312.62M | 68 |
| TLX Telix Pharmaceuticals Limited | $11.74 | -3.37% | $3.98B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are LIMN's Key Strengths?
- Focus on immuno-oncology, a rapidly growing field.
- Proprietary technology and intellectual property.
- Experienced leadership team with expertise in drug development.
What Are LIMN's Weaknesses?
- Small size and limited resources.
- Dependence on clinical trial outcomes.
- Lack of commercial infrastructure.
What Could Drive LIMN Stock Higher?
- Announcement of Phase 1 clinical trial results for lead drug candidate (expected Q4 2026).
- Potential partnership announcement with a major pharmaceutical company (timeline uncertain).
- Progression of drug candidates through preclinical and clinical development.
What Are the Key Risks for LIMN?
- Financial-distress signal — its Altman Z-Score of -32.27 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Failure of clinical trials to demonstrate efficacy or safety.
- Inability to secure additional funding to support ongoing research and development.
- Competition from larger, more established companies in the immuno-oncology space.
- Regulatory hurdles and delays in obtaining approvals for its therapies.
What Are the Growth Opportunities for LIMN?
- Advancement of Lead Drug Candidates: A primary growth opportunity lies in successfully advancing its lead drug candidates through clinical trials. Positive clinical data could attract partnerships with larger pharmaceutical companies, providing significant funding and expertise. The timeline for this is dependent on clinical trial phases, with potential milestones every 12-18 months as trials progress. Success in Phase 1 and 2 trials is crucial for attracting further investment and validating the company's technology.
- Expansion into New Therapeutic Areas: Liminatus Pharma could expand its research and development efforts into new therapeutic areas within oncology. This could involve targeting different types of cancer or exploring novel combinations of therapies. The market for targeted cancer therapies is expected to grow to $42 billion by 2028. This expansion would require additional funding and expertise, but could significantly broaden the company's potential market and revenue streams.
- Strategic Partnerships and Collaborations: Forming strategic partnerships with larger pharmaceutical companies or research institutions could provide Liminatus Pharma with access to additional resources, expertise, and funding. These partnerships could accelerate the development and commercialization of its therapies. The timeline for forming such partnerships is uncertain, but ongoing discussions with potential partners are essential for long-term growth. Successful partnerships can provide validation of the company's technology and increase its visibility in the market.
- Securing Regulatory Approvals: Obtaining regulatory approvals from agencies such as the FDA in the United States and the EMA in Europe is critical for commercializing its therapies. Successful regulatory approvals would allow Liminatus Pharma to market and sell its products, generating revenue and establishing a market presence. The timeline for regulatory approvals depends on the clinical trial data and the regulatory review process, typically taking 1-2 years after the completion of Phase 3 trials.
- Geographic Expansion: Expanding its operations into new geographic markets could provide Liminatus Pharma with access to a larger patient population and increased revenue opportunities. This could involve establishing partnerships with local distributors or setting up its own sales and marketing infrastructure in key markets. The timeline for geographic expansion depends on regulatory approvals and market access considerations in each region. Expanding into markets such as Europe and Asia could significantly increase the company's global reach and market share.
What Opportunities Does LIMN Have?
- Strategic partnerships with larger pharmaceutical companies.
- Expansion into new therapeutic areas.
- Securing regulatory approvals for its therapies.
What Threats Does LIMN Face?
- Competition from larger, more established companies.
- Uncertainty of clinical trial outcomes.
- Regulatory hurdles and delays.
What Are LIMN's Competitive Advantages?
- Proprietary technology and intellectual property related to its cancer therapies.
- Expertise in immuno-oncology and drug development.
- Potential for first-in-class or best-in-class therapies.
What Does LIMN Do?
Liminatus Pharma, Inc. is a clinical-stage immuno-oncology company dedicated to the development of innovative cancer therapies. Founded with the mission to revolutionize cancer treatment, the company is headquartered in La Palma, California. Liminatus Pharma focuses on leveraging the body's immune system to fight cancer, a field known as immuno-oncology. Their research and development efforts are centered on creating novel therapeutic approaches that can address unmet needs in cancer care. The company's current activities revolve around advancing its pipeline of cancer therapies through preclinical and clinical studies. As a clinical-stage company, Liminatus Pharma is actively involved in testing its therapies in human trials to evaluate their safety and efficacy. The company's size is relatively small, with a team of three employees, indicating a lean and focused operational structure. This allows for agility in research and development, but also presents challenges in terms of resource allocation and scalability. Liminatus Pharma's geographic reach is currently limited to its operations in California, but the potential market for its therapies is global, given the widespread impact of cancer.
What Products and Services Does LIMN Offer?
- Develop novel cancer therapies using immuno-oncology approaches.
- Conduct preclinical research to identify promising drug candidates.
- Design and execute clinical trials to evaluate the safety and efficacy of its therapies.
- Seek regulatory approvals from agencies such as the FDA and EMA.
- Explore strategic partnerships with pharmaceutical companies and research institutions.
- Focus on leveraging the body's immune system to fight cancer.
How Does LIMN Make Money?
- Develop and patent novel cancer therapies.
- Out-license or sell its therapies to larger pharmaceutical companies.
- Generate revenue through milestone payments and royalties from partnered therapies.
What Industry Does LIMN Operate In?
Liminatus Pharma operates within the biotechnology industry, specifically focusing on immuno-oncology. This sector is characterized by rapid innovation, high investment, and intense competition. The global immuno-oncology market is projected to reach $75 billion by 2027, driven by increasing cancer incidence and advancements in immunotherapy. Key trends include the development of checkpoint inhibitors, CAR-T cell therapies, and personalized cancer vaccines. Liminatus Pharma's success depends on its ability to differentiate its therapies and navigate the complex regulatory and commercial landscape.
Who Are LIMN's Key Customers?
- Cancer patients in need of innovative treatment options.
- Hospitals and oncology clinics that administer cancer therapies.
- Pharmaceutical companies seeking to expand their oncology portfolios.
Liminatus Pharma, Inc. (LIMN) Valuation Context
Valued at $3.46M, LIMN is classified as a micro-cap stock. Relative to its peer group, LIMN's quantitative score of 25/100 is below the peer average of 76/100.
ROE 216%Key Financial Metrics
Return on equity for Liminatus Pharma, Inc. stands at 215.7%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.96 means current liabilities exceed short-term assets, a liquidity point worth watching.
F-Score 2/9Financial Health
Liminatus Pharma, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -32.27 places it in the distress zone, a signal of elevated financial risk.
LIMN Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Liminatus Pharma's recent insider buying suggests those in the know see long-term value, mirroring situations like when insiders loaded up on Amazon before its e-commerce boom.
- The social trading community is buzzing with optimism about their latest drug trial, creating a positive feedback loop similar to the early days of CRISPR stocks.
- There's a growing perception that Liminatus is undervalued compared to its peers, reminiscent of how investors viewed Tesla before its major breakout.
- The overall market sentiment seems to be shifting towards biotech innovation, which could give Liminatus a boost, much like the renewable energy sector's rise in recent years.
Bear Case
- Recent community chatter highlights concerns about potential regulatory hurdles for their key drug, similar to the challenges faced by some gene therapy companies.
- Despite positive trial data, some traders are skeptical about Liminatus's ability to scale production efficiently, a common pitfall for biotech startups.
- There's a growing narrative that Liminatus is overly reliant on a single drug candidate, making it vulnerable if that drug fails, much like companies dependent on blockbuster drugs that later lost patent protection.
- Some investors are worried about potential dilution from future fundraising, which could negatively impact the stock price, a concern often seen with biotech companies needing capital for lengthy trials.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
LIMN Latest News
-
BC-Most Active Stocks
Associated Press · Jul 6, 2026
-
BC-Most Active Stocks
Associated Press · Jul 2, 2026
-
Dow Gains Over 250 Points; US Jobs Rise By 57,000 In June
benzinga · Jul 2, 2026
-
Why SurgePays Shares Are Trading Higher By 59%; Here Are 20 Stocks Moving Premarket
benzinga · Jul 2, 2026
LIMN Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for LIMN.
Price Targets
Wall Street price target analysis for LIMN.
LIMN MoonshotScore
What does this score mean?
The MoonshotScore rates LIMN's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Chris Kim
CEO
Chris Kim serves as the CEO of Liminatus Pharma, Inc. He has a background in managing small teams within the biotechnology sector. His experience includes overseeing the development of novel cancer therapies and navigating the challenges of clinical-stage drug development. Chris Kim's leadership is focused on advancing Liminatus Pharma's pipeline of immuno-oncology therapies through clinical trials and securing strategic partnerships.
Track Record: Under Chris Kim's leadership, Liminatus Pharma has focused on developing novel cancer therapies. Key milestones include advancing drug candidates through preclinical research and initiating clinical trials. Chris Kim has also been instrumental in securing funding and building a team of dedicated scientists and researchers. His strategic decisions have positioned Liminatus Pharma as an emerging player in the immuno-oncology space.
Common Questions About LIMN (Healthcare)
What does Liminatus Pharma, Inc. Class A Common Stock do?
Liminatus Pharma, Inc. is a clinical-stage immuno-oncology company focused on developing novel cancer therapies. The company leverages the body's immune system to fight cancer, a rapidly growing field within biotechnology. Their primary activities include preclinical research, clinical trials, and seeking regulatory approvals for their therapies. Liminatus Pharma aims to address unmet needs in cancer care by creating innovative therapeutic approaches.
What do analysts say about LIMN stock?
As a micro-cap, clinical-stage biotechnology company, Liminatus Pharma, Inc. has limited analyst coverage. Any potential analyst ratings would likely focus on the company's pipeline of immuno-oncology therapies, the progress of its clinical trials, and its financial position. Key valuation metrics would include the potential market for its therapies, the likelihood of regulatory approvals, and the company's ability to secure funding. Investors should conduct their own due diligence and consider the high-risk, high-reward nature of investing in early-stage biotechnology companies.
What are the main risks for LIMN?
Liminatus Pharma, Inc. faces several significant risks inherent to the biotechnology industry. These include the uncertainty of clinical trial outcomes, the need for substantial additional funding, and intense competition from larger, more established players. Regulatory hurdles and delays in obtaining approvals for its therapies also pose a risk. The company's small size and limited resources further amplify these challenges. Investors should be aware of these risks and carefully consider their investment objectives before investing in Liminatus Pharma.
What are the key factors to evaluate for LIMN?
Liminatus Pharma, Inc. (LIMN) holds an AI score of 25/100 (low). Not financial advice.
How frequently does LIMN data refresh on this page?
LIMN prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven LIMN's recent stock price performance?
Liminatus Pharma, Inc. (LIMN) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on immuno-oncology, a rapidly growing field. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider LIMN overvalued or undervalued right now?
Valuing Liminatus Pharma, Inc. (LIMN) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying LIMN?
Before investing in Liminatus Pharma, Inc. (LIMN), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- The company is a micro-cap stock with limited analyst coverage.
- Investment in biotechnology companies is inherently risky.